



Pharmaids Pharmaceuticals Limited

Date: 09.11.2022

To
Corporate Relations Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400001

Ref: BSE Scrip Code – 524572

Dear Sir / Madam

Subject: Outcome of Board Meeting – November 09, 2022

In continuation to our intimation dated November 02, 2022 regarding the Notice for the Board Meeting, we would like to inform you that the Board of Directors (“Board”) of Pharmaids Pharmaceuticals Limited (the “Company”) at its Meeting held today i.e. Wednesday, November 09, 2022 has inter-alia, considered and approved the Unaudited Financial Results along with the Limited Review Report for the Quarter and Half Year ended September 30, 2022 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) which has been duly reviewed and recommended by the Audit Committee.

We are enclosing herewith the Unaudited Financial Results along with the Limited Review Report signed by M/s PPKG & Co, Statutory Auditors of the Company.

The Board Meeting commenced at 11:30 A.M. and the agenda items for approval of the above-mentioned items were concluded at 12:30 P.M.

The Financial Results are also available on the website of the Company at www.pharmaids.com and on the website of BSE www.bseindia.com

Kindly take the same on your record.

Thanking You

For Pharmaids Pharmaceuticals Limited

VENKATA RAO
SADHANALA
Digitally signed
by VENKATA RAO
SADHANALA
Date: 2022.11.09
12:33:46 +05'30'

S Venkata Rao
Director
DIN: 02906370

Office Address : 503, Amrutha Estate, Himayath Nagar, Hyderabad - 500029. Ph: 040 - 40122151
CIN No: L52520TG1989LC009679, GSTIN No : 36AABCP4657N2ZW
Email : pharmaids125@gmail.com , Web : www.pharmaids.com



Pharmaids Pharmaceuticals Limited

Statement of Unaudited Financial Results for the Quarter and Half-Year ended September 30, 2022

Particulars	Amount in Lakhs					
	Quarter ended			Six Months ended		Year ended
	30-Sep-2022	30-Jun-2022	30-Sep-2021	30-Sep-2022	30-Sep-2021	31-Mar-2022
	Unaudited (Reviewed)	Unaudited (Reviewed)	Unaudited (Reviewed)	Unaudited (Reviewed)	Unaudited (Reviewed)	Audited
Income						
Revenue from Operations	-	-	57.12	-	291.28	393.93
Other Income	-	-	-	-	-	1.51
Total Income	-	-	57.12	-	291.28	395.44
Expenses						
Cost of Material Consumed	-	-	-	-	-	-
Purchase of Stock-in-Trade	-	-	64.37	-	307.27	409.00
Changes in Inventory of Finished Goods, Work-in-progress and Stock-in-trade	-	-	-20.72	-	-41.57	-51.85
Employee Benefit Expenses	31.55	2.08	1.77	33.63	3.54	10.44
Finance Costs	0.02	0.26	-	0.28	-	0.27
Depreciation	0.63	0.08	0.38	0.71	0.75	0.92
Other Expenses	21.98	3.38	3.99	25.36	9.72	12.63
Total Expenses	54.18	5.80	49.78	59.98	279.72	381.41
Profit / (Loss) Before Exceptional Items and Tax	-54.18	-5.80	7.34	-59.98	11.57	14.03
Exceptional items	-	-	-	-	-	-
Profit / (Loss) Before Tax	-54.18	-5.80	7.34	-59.98	11.57	14.03
Tax Expenses:						
(1) Current Tax	-	-	-	-	-	-
(2) Deferred Tax	0.36	8.48	0.07	8.84	3.28	-0.48
Profit / (Loss) for the period from Continuing Operations	-54.54	-14.28	7.27	-68.82	8.28	14.51
Profit / (Loss) from Discontinued Operations	-	-	-	-	-	-
Tax Expense of Discontinued Operations	-	-	-	-	-	-
Profit / (Loss) from Discounting Operations (After Tax)	-	-	-	-	-	-
Profit / (Loss) for the Period	-54.54	-14.28	7.27	-68.82	8.28	14.51
Other Comprehensive Income	-	-	-	-	-	-

Office Address : 503, Amrutha Estate, Himayath Nagar, Hyderabad - 500029. Ph: 040 - 40122151

CIN No: L52520TG1989LC009679, GSTIN No : 36AABCP4657N2ZW

Email : pharmaids125@gmail.com , Web : www.pharmaids.com



Pharmaids Pharmaceuticals Limited

Total Comprehensive Income for the Period	-	-	-	-	-	-
(Profit / Loss + Other Comprehensive Income)	-	-	-	-	-	-
Earnings Per Equity Share (For Continuing Operations)						
a) Basic	-	-	0.07	-	0.08	0.14
b) Diluted	-	-	0.07	-	0.08	0.14
Earnings Per Equity Share (For Discontinued Operations)						
a) Basic	-	-	-	-	-	-
b) Diluted	-	-	-	-	-	-
Earnings Per Equity Share (For Discontinued and Continuing Operations)						
a) Basic	-	-	0.07	-	0.08	0.14
b) Diluted	-	-	0.07	-	0.08	0.14

NOTES:

1. The above Unaudited Standalone Financial Results of the Company were reviewed by the Audit Committee and approved by the Board of Directors at their respective Meetings held on November 9, 2022.
2. The above Unaudited Standalone Financial Results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as amended, prescribed under Section 133 of the Companies Act, 2013, read with the relevant Rules, issued thereunder.
3. The Company has only one reportable segment.
4. As required under Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, the Limited Review by the Statutory Auditors has been completed and the Unmodified Report forwarded to BSE. The said Report does not have any impact on the above Results and Notes which needs explanation.
5. Figures for the previous periods have been regrouped / reclassified wherever considered necessary.

Date: November 9, 2022

Place: Hyderabad

For Pharmaids Pharmaceuticals Limited

VENKATA
RAO
SADHANALA

Digitally signed by
VENKATA RAO
SADHANALA
Date: 2022.11.09
12:34:27 +05'30'

S Venkata Rao
Director



Pharmaids Pharmaceuticals Limited

BALANCE SHEET AS AT SEPTEMBER 30, 2022

(Amount in Lakhs)

	Particulars	Note	As at 30.09.2022	As at 31.03.2022
1	ASSETS			
	Non-Current Assets			
	(a) Property, Plant and Equipment		11.70	3.06
	(b) Capital Work-in-progress		45.00	45.00
	(c) Investment Property		-	-
	(d) Goodwill		-	-
	(e) Other Intangible Assets		-	-
	(f) Intangible Assets under Development		-	-
	(g) Biological Assets other than Bearer Plants		-	-
	(h) Financial Assets		-	-
	Investments		-	-
	Trade Receivables		131.95	141.62
	Loans		569.60	619.23
	Others (to be specified)		-	-
	(i) Deferred Tax Assets (Net)		26.72	35.55
2	Current Assets		-	-
	(a) Inventories		88.76	88.76
	(b) Financial Assets		-	-
	(i) Investments		-	-
	(ii) Trade Receivables		-	133.87
	(iii) Cash and Cash Equivalents		45.15	40.74
	(iv) Bank Balances other than (iii) above		-	-
	(v) Loans and Advances		-	-
	(c) Current Tax Assets (Net)		-	-
	(d) Other Current Assets		8.90	3.39
	Total Assets		927.79	1,111.23
	EQUITY AND LIABILITIES			
	(a) Equity Share Capital		1,026.88	1,026.88
	(b) Other Equity		(228.54)	(159.72)
	LIABILITIES			
1	Non-Current Liabilities			
	(a) Financial Liabilities			
	Borrowings		100.00	-
	Trade Payables		-	-
	(iii) Other Financial Liabilities (other than those specified in item (b), to be specified)		-	-
	(b) Provisions		-	-
	(c) Deferred Tax Liabilities (Net)		-	-
	(d) Other Non-Current Liabilities		-	-
2	Current Liabilities			
	(a) Financial Liabilities			
	Borrowings		-	-
	Trade Payables		3.95	230.58
	(iii) Other Financial Liabilities (other than those specified in item (c))		-	-
	(b) Other Current Liabilities		25.49	13.49
	(c) Provisions		-	-
	(d) Current Tax Liabilities (Net)		-	-
	Total Equity and Liabilities		927.79	1,111.23

Office Address : 503, Amrutha Estate, Himayath Nagar, Hyderabad - 500029. Ph: 040 - 40122151

CIN No: L52520TG1989LC009679, GSTIN No : 36AABCP4657N2ZW

Email : pharmaids125@gmail.com , Web : www.pharmaids.com



Pharmaids Pharmaceuticals Limited

Date: November 9, 2022

Place: Hyderabad

For Pharmaids Pharmaceuticals Limited

VENKATA
RAO
SADHANALA

Digitally signed by
VENKATA RAO
SADHANALA
Date: 2022.11.09
12:34:51 +05'30'

S Venkata Rao
Director



Pharmaids Pharmaceuticals Limited

CASH FLOW STATEMENT

	Particulars	As at 30.09.2022 (Unaudited)	As at 30.09.2021 (Unaudited)
A	CASH FLOW FROM OPERATING ACTIVITIES:		
	Net Profit Before Tax	- 59.98	11.57
	Adjustment for: Interest Charged	-	-
	Depreciation and Amortization Expense	0.71	0.75
	Interest Income	-	-
	Deferred Tax	-	-
	Operating Profit before change in Working Capital	- 59.27	12.32
	Working Capital Changes: Changes in Provisions	-	-
	Changes in Inventories	-	-41.57
	Changes in Trade Receivables	143.54	-55.23
	Change in Short Term Loans and Advances	49.63	-30.78
	Changes in Trade Payables	- 226.63	67.08
	Changes in Other Liabilities	12.00	1.76
	Changes in Other Current Assets	- 5.51	-3.11
	Cash generated from Operations	- 86.24	-49.53
	Direct Tax Paid (Net of Refunds)	-	-
	Net Cash Inflow from Operating Activities (A)	- 86.24	-49.53
B	CASH FLOW FROM INVESTING ACTIVITIES:		
	Interest Received	-	-
	Dividend Income /Gain on Sale of Investments received	-	-
	Purchase of Property, Plant and Equipments, Intangible Assets	- 9.35	-
	Intangible Assets under Development	-	-
	Long Term Loans and Advances (Given) / Repaid	-	37.98
	Net Cash Inflow from Investing Activities (B)	- 9.35	37.98
C	CASH FLOW FROM FINANCING ACTIVITIES:		
	Proceeds from Borrowings	100.00	1.51
	Net increase / (decrease) in Working Capital Demand Loans	-	-
	Payment of Lease Liabilities	-	-
	Increase in Bank Balances other than Cash and Cash Equivalents	-	-
	Dividends Paid (including Distribution Tax)	-	-
	Interest and other Finance Costs (including Borrowing Cost Capitalised)	-	-
	Net Cash Inflow from Financing Activities (C)	100.00	1.51
I	Net (decrease) / increase in Cash and Cash Equivalents (A+B+C)	4.41	-10.04
II	a) Cash and Cash Equivalents at the beginning of the Year	40.74	20.03
	b) Effect of Exchange difference on Restatement of Foreign Currency	-	-
	c) Effect of Fair Value change of Investment held for Trading	-	-
III	Cash and Cash Equivalents at the end of the Year / Period (I+II)	45.15	9.99
IV	Cash and Cash Equivalents at the end of the Year / Period		
	Balances with Banks	37.60	3.22
	Cash-in-hand	7.55	6.77
	Total Cash and Cash Equivalents	45.15	9.99

Office Address : 503, Amrutha Estate, Himayath Nagar, Hyderabad - 500029. Ph: 040 - 40122151

CIN No: L52520TG1989LC009679, GSTIN No : 36AABCP4657N2ZW

Email : pharmaids125@gmail.com , Web : www.pharmaids.com

**INDEPENDENT AUDITOR'S REVIEW REPORT ON
REVIEW OF INTERIM FINANCIAL RESULTS**

To
The Board of Directors,
Pharmaids Pharmaceuticals Limited

We have reviewed the accompanying statement of unaudited Financial Results of **PHARMAIDS PHARMACEUTICALS LIMITED** ("the Company") for the quarter and half year ended 30th September, 2022 ("the Statement"), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed necessary procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

Based on our review conducted as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad

Date: 9-11-2022

UDIN: 22205140BCOULU8439

For PPKG & CO

Chartered Accountants

FRN No. 009655S

Girdharilal Toshniwal

GIRDHARILAL TOSHNIWAL

(Partner)

M. No. 205140